Catalpol Attenuates Pulmonary Fibrosis by Inhibiting Ang II/AT₁ and TGF-β/Smad-Mediated Epithelial Mesenchymal Transition.

ABSTRACT:

Background

Idiopathic pulmonary fibrosis (IPF) is a progressive and devastating chronic lung condition affecting over 3 million people worldwide with a high mortality rate and there are no effective drugs. Angiotensin II (Ang II), as a major effector peptide of the renin angiotensin aldosterone system, has been shown to act in tandem with the transforming growth factor-β (TGF-β) signaling pathway to promote the infiltration of inflammatory cells, production of reactive oxygen species (ROS) and profibrotic factors after lung injury, and to participate in the process of epithelial mesenchymal transition (EMT). Catalpol (CAT) has been shown to have anti-inflammatory and antifibrotic effects. However, the effects and mechanisms of CAT on pulmonary fibrosis are not clear.

Purpose

SUBMITTER: Yu Q 

PROVIDER: S-EPMC9171363 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature